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Abstract 
Standard quality assurance (QA) of cryopreserved peripheral blood stem cells (PBSC) uses 
post-thaw viable CD34+ cell counts. In 2013, concerns arose at Great Ormond Street Hospital 
(GOSH) about 8 patients with delayed engraftment following myeloablative chemotherapy 
with cryopreserved cell rescue, despite adequate post-thaw viable cell counts in all cases. 
Root cause analysis was undertaken; investigations suggested the freeze process itself was a 
contributing factor to suboptimal engraftment. Experiments were undertaken in which a 
single PBSC product was divided into three and cryopreserved in parallel using a control-rate 
freezer (CRF) or passive freezing method (-80°C freezer) at GOSH, or the same passive 
freezing at another laboratory. Viable CD34+ counts were equivalent and adequate in each. 
CFU-GM assays demonstrated colonies from the products cryopreserved using passive 
freezing (both laboratories), but no colonies from products cryopreserved using the CRF. The 
CRF was shown to be operating within manufacturer’s specifications with freeze-profile 
within acceptable limits. This experience has important implications for quality assurance for 
all transplant programmes, particularly those using cryopreserved products. The failure of 
post-thaw viable CD34+ counts, the most widely used routine QA test available, to ensure 
PBSC function is of great concern and should prompt reassessment of protocols and QA 
procedures. 
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Introduction 
Myeloablative chemotherapy is an important component of treatment for a number of 
diagnoses in adult and paediatric oncology. Bone marrow reconstitution following 
chemotherapy is typically achieved with the reinfusion of cryopreserved autologous 
peripheral blood stem cells (PBSC) previously obtained by apheresis; cryopreserved cells are 
less commonly used in the setting of allogeneic transplants (Watt et al, 2007). The procedures 
involved in haematopoietic progenitor cell (HPC) transplantation are governed by 
international standards produced by FACT (Foundation for the Accreditation of Cell 
Therapy) and JACIE (Joint Accreditation Committee of International Society of Cellular 
Therapy [ISCT] and European Society for Bone Marrow Transplantation [EBMT]). These 
standards require accredited cell therapy laboratories (CTLs) to have policies and procedures 
in place for cell cryopreservation and release for clinical use. Viable CD34 enumeration 
assays are a mandatory standard for the collection of HPC products (JACIE v.6 standard 
D8.1.3.2)1, almost universally met using flow cytometric measurement of CD34+ cells and 
7AAD (7-aminoactinomycin D) viability stain (Gratama et al, 2003; Barnett et al, 1998; 
Serke & Johnsen, 2001). Criteria for testing cryopreserved cells are, however, much less well 
defined, with most centres using post-thaw viable CD34 enumeration rather than functional 
testing such as colony assays (Lee et al, 2008; Allan et al, 2002). Post-thaw CD34-viability 
counts are reported to correlate well with colony assays and may be more predictive for 
engraftment outcome (Yang et al, 2005).  
Great Ormond Street Hospital (GOSH) is one of the largest paediatric oncology centres in 
Europe undertaking approximately 20 autologous and 70 allogeneic transplants annually and 
is accredited by JACIE and UK Human Tissue Authority (HTA) regulatory bodies. Patients 
undergo apheresis as in-patients, with cells processed and cryopreserved on-site by the 
clinical CTL before storage in liquid nitrogen vapour phase (LNVP). In October 2013, a 
series of patients with unusually delayed bone marrow reconstitution following reinfusion of 
cryopreserved stem cells was identified. This prompted the declaration of a Serious Incident2 
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and a detailed analysis of transplant programme processes. The transplantation centre at 
University College London Hospital (UCLH) routinely performs HPC colony assays and 
undertook a joint investigation with GOSH that included these functional tests.      
 
Patients and Methods 
In October 2013, a series of 6 patients undergoing myeloablative chemotherapy with 
autologous PBSC rescue at GOSH who experienced significantly delayed count recovery was 
identified (see Table I). An additional patient also underwent autologous transplant during 
this period and recovered promptly (15 days to ANC >0.5x109/L, 28 days to platelets 
>20x109/L). Of note, PBSC for this patient were cryopreserved elsewhere and transferred 
frozen to GOSH for storage and re-infusion. Two additional patients were subsequently 
identified who had received cryopreserved allogeneic bone marrow-derived HPCs and also 
experienced delayed engraftment. In each of these 8 patients, stem cell viability assessed by 
CD34+ 7-AAD vital dye flow cytometry on a pilot vial sample defrosted at the time of 
administration of the cell product confirmed adequate post-thaw viable CD34+ cell doses of 
≥2.5x106/kg in all cases suggesting satisfactory cryopreservation. 
Root-cause analysis was undertaken to review all aspects of the transplant process including 
mobilisation, apheresis, cryopreservation, PBSC reinfusion, and patient factors including 
conditioning chemotherapy and concomitant medications; together with external review of 
CTL processes. Information was obtained from hospital paper and computer records and staff 
interviews. 
Despite satisfactory thaw viable CD34 doses, the involvement of two allogeneic transplant 
patients who had received cryopreserved products and the successful marrow reconstitution in 
a patient who received PBSC that had been cryopreserved elsewhere suggested a potential 
problem with cryopreservation by the GOSH CTL. Consequently, cryopreservation was 
suspended whilst investigations were undertaken. Review of laboratory processes showed no 
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deviations from standard quality control (QC) practices, no recent change in cell handling 
protocols, reagents or equipment, and no common individual responsible for cell processing 
in all cases.   
Fresh and thaw viable CD34 assays 
CD34 assays for cell counts and viability (assessed by 7AAD) were undertaken using 
standard flow cytometry methods (BD FACS Canto II flow cytometer and antibodies from 
BD, Oxford, UK). Daily internal quality control used the stem cell control kit (BD), with 
external QC for CD34 counts via participation in the NEQAS scheme3. Cryopreserved pilot 
vials were defrosted using a 370C waterbath prior to assay. 
Short-Term Colony Forming Cell Assays (CFC) 
Colony Forming Unit-Granulocyte-Monocyte (CFU-GM) assays were used to assess potency. 
These assays were set up by dilution of fresh HPC samples with Iscove’s media and 2% 
human albumin solution (HAS), in the case of thawed samples adding warmed media 
dropwise, to prepare cell plating concentrations of 2.5x104/ml in methylcellulose media 
enriched with growth factors (StemMACS HSC-CFU complete with EPO, Miltenyi Biotec) 
(Watts et al, 2002; 2008). Each sample was then dispensed in four 0.5ml aliquots in 24 well 
plates (Costar) and colonies counted after 14 days incubation at 370C in a 4% C02 
atmosphere, taking the mean of the four well readings as the colony number/well.  
Stored clinical harvest testing 
There were no additional test vials or unused cells available for colony assays from the 
affected patients and in the first investigation five clinical autologous PBSC harvests that had 
been cryopreserved and stored at GOSH and were not required for clinical use (so would 
otherwise have been discarded as per hospital protocol) were thawed and tested for viable 
CD34+ cell counts and colony assays.    
Split fresh apheresis product cryopreservation experiments      
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In subsequent experiments cells from fresh single apheresis cell products were divided into 
three and processed in parallel. To obtain the most immediately relevant clinical information 
these tests were performed using the same routine methods, materials and scale used for 
processing PBSC for clinical use. Excess fresh PBSCs are not frequently available. To ensure 
that experiments were completed in a reasonable timescale, two products used were CD34-
poor flow-through ‘waste’ fractions of two clinical CD34-purification procedures (Watts et 
al, 2002) run at UCLH (known to have low progenitor numbers), and in the remaining cases 
were collections where there was an excess of progenitors above clinical requirement so that 
the surplus cells (which would otherwise have been discarded) could be used for these assays. 
In each experiment, the cell product was mixed with an equal volume of cryoprotectant (20% 
dimethyl sulfoxide (DMSO) in HAS) at 4°C (Watt et al, 2007), transferred to a clinical 
cryobag (CryoMACS, Miltenyi Biotec, Bisley, UK), inserted in its supplied overwrap bag and 
then placed in stainless steel heat-transfer plates for freezing. In three of the paired freeze 
experiments, thermocouple probes were placed inside the secondary overwrap to record the 
sample cooling curves (A&D50 temperature logger with T1 thermocouple, A&D Company, 
Japan). Thereafter, cells were frozen using either a controlled-rate freezer (Kryo560, Planer 
plc, Sunbury-on-Thames, UK) or were placed directly into a -80°C freezer (passive freezing) 
at GOSH. A third aliquot of the cells was frozen using identical passive freezing at UCLH. 
After 7 days, each cryopreserved aliquot was defrosted and assessed for cell viability by 
trypan blue exclusion assay and for total white cell count. Functional activity of PBSCs was 
determined using CFU-GM assays. In additional experiments, a single apheresis cell product 
was again cryopreserved in parallel, using either passive freezing or controlled-rate freezer 
with the programme altered to match profiles used at other UK laboratories or to mimic the 
passive freeze profile (‘CRF passive freeze mimic’). 
 
Statistical methods 
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Differences between engraftment times for historical cohorts were evaluated by Mann-
Whitney U test using Prism 5 software (Graphpad), with values of P<0.05 being considered 
significant. 
 
Results 
External review of processes failed to identify an obvious cause for delayed engraftment in 
these patients. The first investigation in collaboration with UCLH was to test clinical harvests 
cryopreserved at GOSH contemporaneously with the affected patients for colony activity 
(Table II). Five such harvests were available for analysis and in all good viable thaw CD34+ 
cell doses were confirmed but all showed unexpectedly poor CFU-GM numbers (Serke et al, 
1996). This discrepancy was particularly surprising as GOSH and UCLH used the same 
cryopreservation method, reagents, plastics and disposables. However, the centres differed in 
the final freezing step and subsequent investigations focussed on the potential impact of this 
freeze stage in the preservation of clonogenic activity. The freeze process at GOSH used a 
controlled-rate freezer (CRF), in which regulated liquid nitrogen injection is used to reduce 
the temperature of a chamber within the freezer according to a pre-specified programmable 
freeze profile, while the UCLH laboratory used an alternative ‘passive freezing’ method in 
which cells were placed directly into a -80°C freezer. A series of experiments were 
subsequently conducted using available fresh cell products not required for clinical use to 
compare these methods, with cells frozen in parallel using either the CRF or -80°C freezer, 
before being defrosted and assayed. Thermocouple probes were used to record the sample 
cooling curves from the paired products for both freeze methods for comparison purposes. In 
the case of the CRF the sample cooling rates pre- and post-liquid and solid phase transition 
followed the chamber rates closely (Figure 1) and were significantly more rapid than passive 
freezing; mean 5.20C/min versus 1.10C/min (n=3, p=0.0001).  
Although there were no major differences in the WBC concentration or cell viability, CFU-
GM assays demonstrated a clear difference between the methods. Whilst cells cryopreserved 
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using passive freezing at either GOSH or UCLH were capable of growing colonies, CFU-GM 
assays consistently showed no colonies from the cells cryopreserved using the GOSH CRF 
(see Table III). 
In further experiments, the CRF freeze profile was amended to reflect profiles used at other 
UK CTLs (see Figure 2 and Table SI). In two experiments, CFU-GM showed broadly 
equivalent results using the passive freeze method and the CRF with amended profiles: mean 
CFU-GM/well=12 using profile A versus 16 with passive freeze; mean CFU-GM/well=13 
using profile B versus 11 with passive freeze. In a third experiment, the pre-existing GOSH 
CRF profile was compared with an alternative CRF freeze profile program to mirror passive 
freezing. The mean CFU-GM/well=3 using the original GOSH CRF profile was dramatically 
lower than the CFU-GM/well=30 obtained with the ‘CRF passive mimic’ profile, but using 
the same CRF machine. Thus, although functional activity of cells (as estimated by CFU-GM 
assay) cryopreserved using the GOSH CRF appeared significantly reduced compared to those 
cryopreserved using the passive freeze method, this difference did not appear related to the 
operation of the CRF device itself, but rather to the freeze profile. This profile had been used 
in the laboratory since the early 1990s and had not been amended during that time. No 
concerns had previously been raised with the functioning of the CRF and no abnormalities in 
the functioning of the CRF were detected during the investigation or based on its full service 
record history. Nevertheless, in view of the problems that occurred, an alternative 
cryopreservation method based on the passive freezing method in routine use at UCLH since 
1995 was introduced into regular practice at GOSH from the start of 2014. 
In view of the issues raised by the serious incident, we undertook a retrospective review of 
count recovery following all autologous procedures performed at GOSH from 2003–2015. 
During this 13-year period, there were 181 procedures with a median time to neutrophil 
engraftment (ANC >0.5x109/L) of 13 days. There was however marked variation in recovery 
time with 26 (14%) taking >30 days to recover (Figure 3a). Importantly, following suspension 
and subsequent reintroduction of cryopreservation at GOSH at the beginning of 2014, there 
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has been a significant reduction in time to neutrophil engraftment: 2002-2013 median time 13 
days versus 2014-15 median time 11.5 days (p<0.0001 Mann-Whitney, Figure 3c). A similar 
significant reduction in the median time to platelet recovery (>20x109/L unsupported) has 
also been seen: 2010-2013 42 days versus 20 days for 2014-15 (p<0.0001 Mann-Whitney, 
Figure 3b/c). A similar result was obtained when limiting the analysis only to patients 
conditioned with busulfan/melphalan (BuMel), as the largest consistently treated group, 
indicating that this improvement in engraftment was not due to a change in conditioning 
protocols. Comparison of duration of admission (limited to patients conditioned with BuMel) 
also showed a significant reduction from a mean of 43 days in 2002-2013 to 30 days 2014-15 
(p<0.0001, t-test) consistent with more rapid engraftment (Supplementary Figure 1).  
 
Discussion 
Cryopreserved granulocyte colony stimulating factor (G-CSF)-mobilised peripheral blood 
stem cells (PBSC) are used in the vast majority of autologous transplants and a lower 
proportion of allogeneic procedures (Watt et al, 2007). The processes governing transplant 
programmes are closely regulated – such as by JACIE accreditation and, in the UK, the 
Human Tissue Authority. Nevertheless, cell processing and cryopreservation procedures have 
been devised empirically by many individual centres prior to the regulatory era and are poorly 
standardised with the notable exception of standardised flow cytometric CD34+ cell counts 
(Gratama et al, 2003; Barnett et al, 1998). The details of quality control procedures for 
products varies significantly between countries and between laboratories in the same country 
(Rosskopf et al, 2011). Although historically CFU-GM assays were used, based on previously 
available evidence and the real-time and convenient nature of viability assays, the majority of 
laboratories have moved to using quantification of CD34+ cells and confirmation of post-
thaw viability for routine QC. Few laboratories continue to use CFU-GM assays routinely. 
Although CFU-GM for QC provides an indication of the functional activity of PBSC and has 
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proved to be of value in individual centres (Page et al, 2011; Watts et al, 1998; Watts, 1999), 
attempts to introduce inter-laboratory standardisation have been fraught with difficulty 
(Lumley et al, 1999). Based on our experience, we believe, however, that this does not 
preclude a role for CFU-GM assays in direct comparative studies or intermittently as part of 
the on going QC process within CTLs.   
At GOSH, where a transplant programme has been operating for more than 30 years, we 
identified a series of patients with unexpectedly delayed engraftment. In each case, the cells 
reinfused had met standard QC criteria (CD34+ number and viability). In view of the 
involvement of two patients who had received allogeneic cryopreserved products and the 
successful marrow reconstitution in a patient who received PBSC that had been cryopreserved 
elsewhere, a potential problem with cryopreservation at GOSH was identified. Subsequently 
experiments in which cells were cryopreserved in parallel using different freeze methods 
indicated that although PBSC frozen using the GOSH CRF had equivalent viability, their 
functional activity based on CFU-GM was significantly reduced. Ultimately, no problem with 
the CRF device itself was identified and indeed with amended freeze profiles using the same 
machine CFU-GM assays showed equivalent results with other freeze methods.  
The investigation and discussions with other UK CTLs has confirmed that there is no single 
standard freeze profile in use in those laboratories using a CRF for cryopreservation (Figure 
2). The freeze profile and the rate of change of temperature within the cell product is crucial 
for successful cryopreservation with there being a need to balance sufficiently rapid cooling 
to minimise the transition phase, whilst avoiding excessively rapid cooling thereafter (Baust 
et al, 2009). In particular, cooling after the transition phase greater than 5-6°C/min has been 
reported to be associated with CFU-GM loss and delayed re-engraftment after reinfusion into 
patients (Abrams et al, 1980; Gorin et al, 1983). In the current investigation the CRF freeze 
rate did not exceed 50C/min so that the major losses of CFU-GM activity seen is surprising. 
The CRF programme in use at GOSH since the early 1990s was established when bone 
marrow was the exclusive stem cell source at the time of these early reports and it is possible 
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that the more recent use of PBSC could be a factor in greater susceptibility to a lower range of 
freeze rates. In the absence of a ‘gold-standard’ freeze profile, it is imperative that individual 
CTLs have measures in place to validate their methods. Critically, assessment of post-thaw 
CD34+ viability is unlikely to be adequate to guarantee functional activity. 
A recent study using umbilical cord blood (UCB) confirms the negative impact of excessively 
rapid cooling and may be relevant to the clinical incident as an example of major CFU-GM 
activity loss without comparable CD34+ cell death related to rapid freezing conditions. In this 
study the number of viable CD34+ cells was not significantly reduced under any of the 
conditions tested but CFU-GM were specifically and significantly lower if cryopreservation 
using a CRF was interrupted at different temperature points and cells transferred directly to 
liquid nitrogen vapour phase (LNVP, usually below -1500C) if the cells had not reached a 
sufficiently low temperature (-40°C) before the transfer. In contrast, no significant differences 
were seen in CFU-GM or CD34+ cell viability in paired samples transferred to a -80°C 
mechanical freezer from the CRF at any temperature point (Yang et al, 2015).  
We believe that the experiences and subsequent investigation at GOSH have significant 
implications for other CTLs and transplant programmes, and for the cryopreservation of 
UCB, as well as PBSC. It is clear that the widely accepted criteria of thaw CD34+ 
quantification and measurement of viability does not guarantee the functional activity of stem 
cells post-cryopreservation. Real-time collection and analysis of re-engraftment data from 
patients receiving cryopreserved cells is crucial and ultimately only successful bone marrow 
reconstitution confirms the effectiveness of the cryopreservation process. The previous lack 
of such a system for real-time monitoring of outcomes for patients treated at GOSH almost 
certainly contributed to delays in identifying issues with prolonged engraftment times. 
Although it is important for individual centres to review their results, in the paediatric setting 
in particular, the number of procedures undertaken by any individual centre may preclude the 
early appreciation of adverse trends in count recovery. For individual patients with delayed 
engraftment, there is often the possibility of attributing other explanations (such as 
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intercurrent infection) rather than investigating a potential underlying issue with 
cryopreservation. Consequently, in the UK there is a plan to develop a prospective national 
audit process for paediatric autografts; a retrospective audit of engraftment following 
paediatric autografts is also underway. 
CRF profiles may involve several multi-stage cooling ramps and it is difficult to establish the 
‘optimal freeze profile’ but the findings of this study support recommendations that the post-
fusion rate should be between 1-20C/min rate down to at least -400C (Rowley, 1992). Passive 
freezing at a fixed temperature such as -800C does not allow the same degree of precision and 
documentation as CRF but has the advantages of low cost, simplicity and more rapid 
throughput. It also represents an option for validation in that a CRF programme that fails to 
preserve clonogenic activity at least as effectively as passive freezing should be subject to 
review. 
The GOSH laboratory has now moved to using a passive freezing technique. Previous studies 
have suggested improved CFU-GM yields and more rapid engraftment with use of a CRF 
rather than passive freeze (Montanari et al, 2003; Perez-Oteyza et al, 1998), although this is 
not supported in other reports (Takaue et al, 1994; Katayama et al, 1997). Crucially, the 
GOSH data on count recovery post-autografts for the period since the beginning of 2014 
when this new cryopreservation process was introduced appear to support the effectiveness of 
this technique. Ultimately, whatever method is used, measurement of post-thaw viable 
CD34+ numbers is not sufficient to guarantee functional activity and laboratories and 
transplant programmes need to be aware of the risk of impaired functional activity of 
cryopreserved stem cells even if they have passed standard QC criteria. The considerable 
variability in processing and cryopreservation between centres represents a major QC 
challenge so that sessional validation of the methods assuring adequate potency of the final 
product is essential. GOSH now stores a second pilot vial on all products. The CTL 
undertakes a CFU-GM on every fifth product as routine QC to monitor ongoing validity of 
the freeze process, as well as undertaking CFU-GM assays on any product where there is 
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delayed engraftment. Of note, however, a small pilot vial may not be representative of the 
whole clinical product (given differences in freeze rate) and therefore further work is required 
to establish a better surrogate sample for potency testing (e.g. by freezing pilot vials using an 
isopropyl alcohol freezing container). 
A new potency assurance standard for cryopreserved products was introduced into the JACIE 
version 6 standards in 20151. This standard could be met by sessional colony assays for HPC 
function however, as previously noted, standardisation issues remain a barrier for widespread 
adoption. In contrast, the standardisation of flow cytometric CD34+ cell counting between 
transplantation centres has been remarkably successful (Gratama et al, 2003; Barnett et al, 
1998) and may present a model for a flow based test where viability relies not on simple 
permeability but on metabolic function such as ALDH and Syto-16 activity. These activities 
have been shown in a number of flow cytometric studies to be closely associated with 
progenitor cell clonogenic activity (de Boer et al, 2002; Schuurhuis et al, 2001; Lee et al, 
2014; Fallon et al, 2003) and may provide the required validation to assure the potency of 
cryopreserved cells in the future.  
Our experience has demonstrated that viability assessment may provide false reassurance of 
the effectiveness of long-established cell product preparation methods. All countries should 
ensure that their regulatory processes include adequate audit and monitoring so that 
deviations can be rapidly detected, particularly in smaller centres where trend analysis may be 
difficult. 
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Table I. Summary of patients with delayed bone marrow reconstitution. ATRT: atypical teratoid rhabdoid tumour. Conditioning: treosulfan (Treo), melphalan 
(Mel), busulfan (Bu), carboplatin (Carbo), fludarabine (Flu), cyclophosphamide (Cy). Cryopreservation date (Cryo date). Number of days to neutrophil 
recovery >0.5x109/L (ANC>0.5) or platelet recovery >20x109/L, at least 7 days after last transfusion (Plt >20). Rescue indicates administration of additional 
PBSC in view of failure of adequate BM reconstitution. ANED: alive with no evidence of disease. 
 
Diagnosis Conditioning Type Day 0 Cryo date 
Fresh 
CD34 
dose 
(x106/
kg) 
Post-
thaw 
CD34 
dose 
(x106/
kg) 
Post-
thaw 
viabil
ity 
D30 
ANC 
(x109/
L) 
Days 
to 
ANC 
>0.5x
109/L 
Days 
to plt 
>20x10
9/L 
Resc
ue? 
Outcome 
Neuroblastoma Treo/Mel Auto Apr 2013 Feb 2013 6.06 7.56a >95% 0.91 30 57 No ANED 
Neuroblastoma Bu/Mel Auto Apr 2013 Mar 2013 3.88 2.94 >95% 0.44 37 53 Yes Prolonged thrombocytopenia, ANED 
Neuroblastoma Bu/Mel Auto Apr 2013 Feb 2013 6.60 6.12 >95% 0.14 41 49 Yes ANED 
ATRT Carbo/Thio Auto Jul 2013 Jun 2013 8.99 7.31 >95% 0.38 38 >50 Yes ANED 
Neuroblastoma Bu/Mel Auto Aug 2013 Apr 2013 4.00 3.39 >95% 0.25 75 >100 Yes Died from recurrent disease 
Neuroblastoma Bu/Mel Auto Aug 2013 Jun 2013 4.21 3.22 >95% 0.59 42 n/a Yes Died from sepsis 
Rel AML Bu/Cy/Mel Allob Mar 2013 Feb 2013 8.56 7.68 88% 0.85 30 >96 No Died from recurrent disease 
Rel ALL Flu/Treo/Thio Alloc Apr 2013 Apr 2013 2.92 2.55 87% 0.12 >78 >78 Yes Died from recurrent disease 
 
a post-thaw CD34 dose greater than fresh due to variability in CD34 count in pilot vials 
b allogeneic bone marrow-derived HPC, CD3 cell dose 11.7x107/kg, 10/10 matched unrelated donor 
c allogeneic bone marrow-derived HPC, CD3 cell dose 2.4x107/kg, 10/10 match unrelated donor  
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Table II.  Thaw viable CD34+ cell and CFU-GM assays of clinical PBSC harvests cryopreserved at GOSH. 
 
Date of 
Cryopreservation 
at GOSH 
Fresh viable 
CD34+ 
count (x106/kg) 
 
Post-thaw 
viable CD34+ 
count (x106/kg) 
 
Post-thaw CD34+ 
viability 
(%age 7AAD-) 
CFU-GM  
(x105/kg) 
30/09/2010  3.4 2.8    94 0.16 
28/09/2011 30.8 26.8  88 0.29  
13/03/2013  4.8 3.6    99 0.58 
19/04/2013 2.0 1.3    99 0.00 
30/07/2013 6.5 6.1    91 0.13 
 
Analysis of the fresh product showed viability (7AAD-) of >98% in all cases 
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Table III: Results of four split-harvest cryopreservation procedures comparing different methods  
 
PBSC sample 
Cryopreservation 
method 
WBC 
(x109/L) 
Viability 
CFU-GM /well CFU-GM x106/ml of product 
(thaw yield) 
Sample 1 Fresh 145 100% 32.8 0.38 (100%) 
 UCLH -80°C freezer 166 78% 17.0 0.23 (59%) 
 GOSH -80°C freezer 175 79% 17.5 0.25 (64%) 
 GOSH CRF 176 77% 0.0 0.00 (0%) 
Sample 2* Fresh 204 99% 5.5 0.09 (100%) 
 UCLH -80°C freezer 239 90% 5.0 0.10 (106%) 
 GOSH -80°C freezer 239 78% 5.25 0.10 (112%) 
 GOSH CRF 242 79% 0.0 0.00 (0%) 
Sample 3* Fresh 210 98% 3.25 0.06 (100%) 
 UCLH -80°C freezer 237 82% 3.5 0.07 (118%) 
 GOSH -80°C freezer 234 64% 2.25 0.04 (47%) 
 GOSH CRF 251 80% 0.0 0.00 (0%) 
Sample 4 Fresh 87 99% 47.0 0.33 (100%) 
 GOSH -80°C freezer 100 76% 28.5 0.23 (70%) 
 GOSH CRF 97 89% 0.0 0.00 (0%) 
 
*Sample 2 and 3 were CD34+ cell poor flow through ‘waste’ cells from two clinical CD34 enrichment CliniMACS procedures run on donor apheresis harvests at UCLH and 
hence lower colony numbers/well and reduced accuracy. 
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Figure 1. Representative cooling curves of clinical scale HPC samples cryopreserved by CRF (separate curves for chamber and sample temperatures) or 
passive freezing. * shows increase in temperature associated with release of latent heat of fusion at phase transition    
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Figure 2 Different freeze profiles  
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Figure 3a Time to neutrophil recovery (ANC>0.5x109/L) over a 13-year period at GOSH. Each point represents a sequential patient undergoing an 
autologous transplant procedure. Shaded area from start of 2014 highlights introduction of revised cryopreservation process. 
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Figure 3b. Time to platelet recovery (platelet>20x109/L unsupported) over period since start of 2010 at GOSH. Each point represents a sequential patient 
undergoing an autologous transplant procedure. Shaded area from start of 2014 highlights introduction of revised cryopreservation process. 
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Figure 3c. Comparison of time to ANC and platelet recovery at GOSH for 2003-2013 (ANC) or 2010-13 (platelets) versus 2014-15.  
*** p<0.0001 (Mann-Whitney) 
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Supplementary Figure 1. Duration of admission for patients receiving cryopreserved PBSC after conditioning with BuMel, 2010-2015. 
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Table SI Comparison of different freeze profiles 
 
 
 GOSH Centre A Centre B Centre C Passive Freeze Mimic 
Start temp +5°C +8°C +4°C +4°C +5°C 
Time 35 mins 60 mins 70 mins 60 mins 80 mins 
Profile 1°C/min to -15°C 2°C/min to 0°C 1°C/min to -30°C 1°C/min to 0°C 1°C/min to -80°C 
 4°C/min to -25°C 1°C/min to -20°C 2°C/min to -100°C 2°C/min to -60°C  
 5°C/min to -35°C 2°C/min to -60°C  4°C/min to -100°C  
 8°C/min to -100°C 4°C/min to -100°C    
 
 
 
15°C/min to -170°C 
 
 
8°C/min to -140°C  
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